CD8A and neoplasm: In 4T1 mammary tumors, high-dose DOX (anthracycline) and methotrexate (antimetabolic) activate the IRF7/interferon (IFN)-β/IFNAR axis, shifting the immune response from MDSCs-dominated to CD4+/CD8+ T cell-dependent anti-tumor response that maintains dormancy 30.